OPTI-2, Injectable HDV-Rapid Acting Insulin
Type 1 Diabetes
Phase 2BActive
Key Facts
About Diasome Pharmaceuticals
Diasome Pharmaceuticals is a clinical-stage biotech leveraging its HDV™ platform to create liver-targeted therapies for metabolic diseases. Its core technology uses a lipid nanoparticle (bicelle) with a biotin tag to selectively deliver drug actives to hepatocytes, aiming to enhance efficacy and reduce side effects by restoring natural physiological pathways. The most advanced program, OPTI-2 (HDV-Rapid Acting Insulin), is in Phase 2b for Type 1 Diabetes, with preclinical programs in GLP-1 and serotonin-based therapies. As a private company, Diasome is positioned to address significant unmet needs in the large and growing diabetes and obesity markets.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |